Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.
Brief Summary: This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.


Options:
A: Arm Label: Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Golimumab 100 mg | Arm Label: GLM-I-Rsp-Golimumab 50 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 50 mg, Biological: Golimumab 100 mg | Arm Label: GLM-I-Rsp-Golimumab 100 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 200 mg | Arm Label: Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Golimumab 100 mg | Arm Label: PBO-I-nonRsp-Golimumab 100 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Arm Label: GLM-I-nonRsp-Golimumab 100 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance, Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): GLM-I-Rsp-Golimumab 50 mg Maintenance | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): GLM-I-Rsp-Golimumab 100 mg Maintenance, GLM-I-Rsp-Golimumab 50 mg Maintenance, GLM-I-nonRsp-Golimumab 100 mg Maintenance, Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance, PBO-I-nonRsp-Golimumab 100 mg Maintenance, Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance | Intervention Type: BIOLOGICAL; Name: Golimumab 200 mg; Assigned to Arm(s): GLM-I-Rsp-Golimumab 100 mg Maintenance
B: Arm Label: tofacitinib 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: tofacitinib | Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: tofacitinib; Assigned to Arm(s): tofacitinib 10 mg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo BID
C: Arm Label: Induction Study - Placebo Intravenous (IV); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo IV | Arm Label: Induction Study - Ustekinumab 130 milligram (mg) IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab IV | Arm Label: Induction Study - Ustekinumab 6 mg/kg IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab IV | Arm Label: Induction Study- Placebo- Nonresponsders at Week 8; Type: OTHER; Interventions: Drug: Placebo SC, Drug: Ustekinumab IV | Arm Label: Induction study-Ustekinumab Nonresponders at Week 8; Type: OTHER; Interventions: Drug: Placebo IV, Drug: Ustekinumab SC | Arm Label: Maintenance Study - Placebo Subcutaneous (SC); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Arm Label: Maintenance Study - Ustekinumab 90mg SC every 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab SC | Arm Label: Maintenance Study - Ustekinumab 90mg SC every 8 weeks (q8w); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab SC | Arm Label: Maintenance Study - Placebo IV - Responder - Placebo SC; Type: OTHER; Interventions: Drug: Placebo SC | Arm Label: Maintenance Study-Delayed Responder-Ustekinumab 90mg SC q8w; Type: OTHER; Interventions: Drug: Ustekinumab SC | Intervention Type: DRUG; Name: Placebo IV; Assigned to Arm(s): Induction Study - Placebo Intravenous (IV), Induction study-Ustekinumab Nonresponders at Week 8 | Intervention Type: DRUG; Name: Placebo SC; Assigned to Arm(s): Induction Study- Placebo- Nonresponsders at Week 8, Maintenance Study - Placebo IV - Responder - Placebo SC, Maintenance Study - Placebo Subcutaneous (SC) | Intervention Type: DRUG; Name: Ustekinumab IV; Assigned to Arm(s): Induction Study - Ustekinumab 130 milligram (mg) IV, Induction Study - Ustekinumab 6 mg/kg IV, Induction Study- Placebo- Nonresponsders at Week 8 | Intervention Type: DRUG; Name: Ustekinumab SC; Assigned to Arm(s): Induction study-Ustekinumab Nonresponders at Week 8, Maintenance Study - Ustekinumab 90mg SC every 12 weeks, Maintenance Study - Ustekinumab 90mg SC every 8 weeks (q8w), Maintenance Study-Delayed Responder-Ustekinumab 90mg SC q8w
D: Arm Label: Placebo Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: CP-690,550 5 mg Arm; Type: EXPERIMENTAL; Interventions: Drug: CP690,550 | Arm Label: CP-690,550 10 mg Arm; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator | Intervention Type: DRUG; Name: CP690,550; Assigned to Arm(s): CP-690,550 5 mg Arm | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 10 mg Arm

Answer: B